FDA Announces New Recommendations for Acceptable Limits of Nitrosamine in Drugs
Guidance comes after a number of massive drug recalls issued in recent years due to nitrosamine contamination, which could increase cancer risks.
Guidance comes after a number of massive drug recalls issued in recent years due to nitrosamine contamination, which could increase cancer risks.
Merck indicates it has identified the cause of nitrosamine contaminants in some batches of Januvia and Janumet, which occurs during the manufacturing and storage process.
The EU and Canada have set daily acceptable limits for all nitrosamines, but the FDA has not. During a meeting this week the U.S. regulators met to discuss how to bets address the problem with nitrosames in drugs.
The cancer-causing contaminant, a nitrosamine, was detected at levels exceeding the daily acceptable allowance set by the FDA, but there will be no recall due to fears of a shortage.
The Accupril recall is the latest in a string of recalls involving hypertension drugs due to nitrosamine contamination, which could increase the risk of cancer with long-term use.
Similar nitrosamine contamination has led to massive Zantac, Chantix, valsartan and metformin recalls in recent years.
Patients with recalled Accuretic pills are being told to continue taking the drug until advised otherwise by a healthcare provider.
Lawsuits claim the presence of nitrosamines make Chantix an adulterated drug never approved by the FDA.
Cancer causing chemical impurity in Chantix, identified as N-nitroso-varenicline, makes stop-smoking drug an illegally manufactured and distributed medication.